Press release
Investigation announced for Investors in shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS)
An investigation on behalf of investors in Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) shares over potential wrongdoing.
Investors who purchased shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Xeris Pharmaceuticals, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Chicago, IL based Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations.
On or around June 20, 2018, Xeris conducted its initial public offering ("IPO"), selling 5,700,000 shares of common stock priced at $15.00 per share.
On March 9, 2021, Xeris Pharmaceuticals, Inc announced its fourth quarter and full year 2020 results. Xeris Pharmaceuticals, Inc. reported that its annual Total Revneue rose from $2.72 million in 2019 to $20.15 million in 2020, and that its Net Loss declined from $125.58 million in 2019 to $91.13 million in 2020. However, Xeris Pharmaceuticals, Inc reported fourth quarter GAAP earnings per share of $0.41, missing consensus estimates by $0.01, and revenue of $7.09 million, missing consensus estimates by $1.82 million.
Shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) declined to $3.98 per share on March 9, 2021.
Those who purchased shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) here
News-ID: 2277801 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Xeris
Glucagon Market Set to Witness Significant Growth by 2032 | Eli Lilly and Compan …
In 2023, the global glucagon market was valued at approximately USD 422.6 million. Projections indicate that the market will reach around USD 742.3 million by 2032, reflecting a compound annual growth rate (CAGR) of 5.9% from 2024 to 2032.
Request a sample copy of this report at: https://www.omrglobal.com/request-sample/glucagon-market
Glucagon Market Overview:
The global glucagon market is experiencing steady growth, driven by its critical role in managing severe hypoglycemia, particularly among individuals with diabetes.…
Auto-Injectors Market Growth in Future Scope 2025-2032 | Sanofi S.A., Takeda Pha …
The global auto-injectors market is estimated to be valued at US$ 4,497.7 million in 2022 and is expected to exhibit a CAGR of 18.0% during the forecast period (2022-2030).
Latest Report, titled "Auto-Injectors Market" Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032, by Coherent Market Insights offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary…
Auto-Injectors Market Detailed In New Research Report 2025 | Sanofi S.A., Takeda …
The latest report, titled "Auto-Injectors Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032" by Coherent Market Insights, offers an in-depth analysis of the industry, providing valuable insights into market dynamics. The study perhaps a perfect mixture of qualitative and quantitative information highlighting key market developments, challenges, competition industry face alongside gap analysis and new opportunities available and trend within the Auto-Injectors Market. This report offers Market size, recent…
Congenital Hyperinsulinism Treatment Market Detailed In New Research Report 2024 …
Congenital Hyperinsulinism Treatment Market Trends Overview 2024-2031:
A new Report by Coherent Market Insights, titled "Congenital Hyperinsulinism Treatment Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Congenital Hyperinsulinism Treatment market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
This report has a complete table of contents, figures, tables, and charts, as…
Post Bariatric Hypoglycemia Market Report 2032: Epidemiology Data, Pipeline Ther …
DelveInsight's "Post Bariatric Hypoglycemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Post Bariatric Hypoglycemia, historical and forecasted epidemiology as well as the Post Bariatric Hypoglycemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Post Bariatric Hypoglycemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Post Bariatric Hypoglycemia…
Congenital Hyperinsulinism Market Accelerating CAGR +4% by 2028 with Teva Pharma …
Congenital Hyperinsulinism Market is projected to thrive at a CAGR +4% by the timeline of 2021-28.
Congenital hyperinsulinism is a rare genetic condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. People with this condition have frequent episodes of low blood sugar (hypoglycemia).
Congenital Hyperinsulinism be cured by diffusing CHI affects the entire pancreas. It can be inherited in a…
